Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01176-6/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ada25&_hsenc=p2ANqtz-8P427_35XSbnPnRxF0JXjd0X26q3W_QG9BAqpM_XUPQUp7yvJxD0NLkkFFdnkgBmqg2CFxJfRy8UsVJP9cZ_XgMZFaVQ&_hsmi=368028124&utm_content=368028124&utm_source=hs_email